Cite

    Zhou, C. et al. (2019). Dynamics of circulating vascular endothelial growth factor‐A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British journal of clinical pharmacology. 85 (8), pp. 1781-1789. [Online].